Calithera Biosciences Appoints Suzy Jones to Board of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Calithera Biosciences Appoints Suzy Jones to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Suzy Jones to the company's Board of Directors, where she will be a member of the company’s Audit Committee.  Ms. Jones is currently Founder and Managing Partner of DNA Ink, a boutique life sciences advisory firm.

"The addition of such a seasoned biotechnology executive will add another key life science expert to our board," said Susan Molineaux, PhD, President and Chief Executive Officer.  "As we advance our tumor metabolism and tumor immunology therapeutics through clinical development, we believe Suzy will make important strategic contributions that will help us develop our pipeline with an eye toward potential product commercialization."

Prior to founding DNA Ink, Suzy spent 20 years at Genentech in various roles in immunology research, product development managing cross functional teams for RITUXAN® and AVASTIN®, and business development where she was Head of Non-Oncology Licensing and later Interim Head of Partnering and Head of Business Development.  Suzy’s group helped to diversify Genentech’s portfolio through licensing. During her time in business development, the group was recognized in an independent IBM survey as the number one deal making and sourcing group in the world.  In 2010, she was named by Black Health Magazine as one of the, “Top 25 Most Influential African Americans in Healthcare, Medicine, Pharmaceutical and Food Industries.”  Suzy serves as a member of the board of directors of Patrys, an ASX listed Australian biotechnology company.  She received a degree in Biology from University of California, Santa Cruz.

About Calithera Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.  Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents.  CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, an immunosuppressive enzyme in myeloid-derived suppressor cells responsible for T-cell suppression.  Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells.  Calithera is headquartered in South San Francisco, California.  For more information about Calithera, please visit www.calithera.com .

Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements.  These statements include those related to Calithera’s advancement of its tumor metabolism and tumor immunology therapeutics through clinical development and development of its pipeline towards potential product commercialization.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.  In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.  Such product candidates may not be beneficial to patients or successfully commercialized.  The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price.  Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Annual Report on Form 10-K for the year ended December 31, 2015, and other periodic filings with the Securities and Exchange Commission at www.sec.gov .  These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Contact: Jennifer McNealey ir@Calithera.com 650-870-1071

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 76

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 163

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 160

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 67

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Significant Information Regarding V.F. Corporation

Updated Category News Views 188

Understanding the Current Situation at V.F. Corporation V.F. Corporation, commonly referred to as VFC, is in the spotlight as claims are being investigated by legal teams representing investors. If you are among those impacted, it is essential to be well-informed and proactive in understanding your options. Losses Exceeding $50,000 - Know Your Rights If you have suffered...

Continue Reading
ImmunityBio Soars as Anktiva Fuels 700% Revenue Surge

Updated Category News Views 182

The Market's Wild Ride with ImmunityBio Talk about a rollercoaster! ImmunityBio Inc. is strutting its stuff—stock's up over 55% in just the past month! This kinda takes me back to the dot-com bust: exciting ventures, bold promises, and whoosh—away we fly! Honestly, you can’t ignore that hefty 700% revenue jump. And get this— their leading drug, Anktiva, is really...

Continue Reading
Understanding the Class Action Lawsuit Involving Elevance Health

Updated Category News Views 329

Investigating the Class Action Lawsuit Against Elevance Health Investors should be aware of the ongoing class action lawsuit involving Elevance Health, Inc. (NYSE: ELV). This lawsuit has been initiated to address significant concerns regarding false and misleading statements made by the company. The deadline for potential lead plaintiffs to participate is approaching, and...

Continue Reading
Sprott's Financial Performance for Q2 2025 Highlights Growth

Updated Category News Views 189

Sprott Inc. Financial Performance Report Sprott Inc. (NYSE/TSX: SII) has released its financial results for the second quarter of 2025. The company demonstrated significant growth with the total assets under management (AUM) rising to $40 billion by the end of June 2025. This marks a substantial 14% increase from $35.1 billion in the previous quarter and a compelling 27%...

Continue Reading
Analyzing Market Sentiment on Novo Nordisk Stocks

Updated Category News Views 239

Understanding Novo Nordisk's Stock Market Landscape Novo Nordisk has been experiencing notable fluctuations in its stock market sentiment. Recent reports indicate a decline in the company's short percent of float by 9.09%. With approximately 6.36 million shares sold short, this accounts for merely 0.2% of its available trading shares. Furthermore, based on the current...

Continue Reading